Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06662812 · ClinicalTrials.gov registry record
Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery Registry
A clinical trial, sponsored by Novartis.
- Completed
- Registry status
- 1,665
- Enrollment target
NCT06662812: Completed study, sponsored by Novartis.
NCT06662812 is a clinical trial that has completed, run by Novartis. The registered enrollment target is 1,665 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06662812 has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- 1,665 participants
- Enrollment target
Study Summary
This was a retrospective observational cohort study. This study was a secondary analysis of individuals with sickle cell disease (SCD) enrolled in the GRNDaD registry.
Primary Outcome
DMTs included: hydroxyurea, voxelotor, crizanlizumab, l-glutamine, and chronic red cell transfusion.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,665 participants |
| Start Date | 2021-10-06 |
| Est. Completion | 2023-12-01 |
What the finished NCT06662812 record still lists
NCT06662812 is an observational study that tracks outcomes without assigning an intervention. Its 1,665 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT06662812 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06662812 about?
NCT06662812 is a clinical study titled "Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery Registry". This was a retrospective observational cohort study. This study was a secondary analysis of individuals with sickle cell disease (SCD) enrolled in the GRNDaD registry.
What is the current status of trial NCT06662812?
This trial is currently completed. The enrollment target is 1,665 participants. The study started on 2021-10-06. Estimated completion is 2023-12-01.
Who is sponsoring clinical trial NCT06662812?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06644625 · 1,665 participants
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
- NCT06034405 · 1,663 participants
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
- NCT04852887 · 1,670 participants · Phase 3
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- NCT06401330 · 1,656 participants · Phase 3
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI